TORONTO,
April 25,
2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), announces that it will release its Q1 fiscal
2024 financial results on Thursday, May 9,
2024. The Company will hold a conference call that same day
at 8:30 a.m. ET to discuss its
results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr.
John Hanna, Interim Chief Financial
Officer. Slides to accompany management's prepared remarks will
be available to view via the webcast.
CONFERENCE ID: 64428
DATE: Thursday, May 9, 2024
TIME: 8:30 a.m. ET
WEBCAST
LINK: https://app.webinar.net/lw3W7LjxZGA
TRADITIONAL DIAL-IN NUMBER: 1-800-836-8184
or 1-289-819-1350
RAPIDCONNECT: To instantly join the
conference call by phone, please use the following URL to easily
register and be connected into the conference call automatically:
https://emportal.ink/3xw9YCV
TAPED REPLAY: 1-888-660-6345 or
1-289-819-1450
REPLAY CODE: 64428#
The taped replay will be available for 14 days
and the archived webcast will be available for 365 days.
A link to the live audio webcast of the
conference call will also be available on the events page of the
investors section of HLS Therapeutics' website at
www.hlstherapeutics.com. Please connect at least 15 minutes prior
to the conference call to ensure adequate time for any software
download that may be required to hear the webcast.
ABOUT HLS THERAPEUTICS
INC.
Formed in 2015, HLS is a pharmaceutical company
focused on the acquisition and commercialization of late-stage
development, commercial stage promoted and established branded
pharmaceutical products in the North American markets. HLS's focus
is on products that address unmet needs in the treatment of
psychiatric disorders and cardiovascular disease. HLS's management
team is composed of seasoned pharmaceutical executives with a
strong track record of success in these therapeutic areas and at
managing products in each of these lifecycle stages. For more
information visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.